Sid Sadler, Cancer Survivor, posted on X:
“A new era for renal cell carcinoma patients!
At ASCO2025, research on predictive biomarkers was shared, focusing on tailoring treatments like pembrolizumab and axitinib for better outcomes. This means more personalized care and hope for those battling advanced RCC.”
More posts featuring ASCO25.